Phase 2 Acute Myeloid Leukaemia (AML) Clinical Trials
10 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–10 of 10 trials
Recruiting
Phase 2Phase 3
L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
Acute Myeloid Leukaemia (AML)
Moleculin Biotech, Inc.312 enrolled25 locationsNCT06788756
Recruiting
Phase 1Phase 2
A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
LeukemiaBlood CancersBlood Cancer+1 more
Jacqueline Garcia, MD31 enrolled2 locationsNCT07148180
Not Yet Recruiting
Phase 2
MDS05/D2 - Phase Ib/II study for treatment of Myelodysplasia (MDS) with SRA515 and ASTX727,
Myelodysplastic Syndrome (MDS)Acute Myeloid Leukaemia (AML)
Australasian Leukaemia and Lymphoma Group (ALLG)86 enrolled1 locationACTRN12622001302741
Not Yet Recruiting
Phase 2
AMLM22/D3 - The International Acute myeloid leukaemia (AML) Platform Consortium (IAPC) trial is a randomised, multi-arm study platform to compare the efficacy of experimental therapies versus standard of care in patients with acute myeloid leukaemia in first complete remission.
Acute Myeloid Leukaemia (AML)
Australian Leukaemia and Lymphoma Group (ALLG)50 enrolled1 locationACTRN12621000246886
Recruiting
Phase 2
AMLM22/D2-The International Acute myeloid leukaemia (AML) Platform Consortium (IAPC) trial is a randomised, multi-arm study platform to compare the efficacy of experimental therapies versus standard of care in subjects with acute myeloid leukaemia in first complete remission. Domain 2 is investigating the safety and efficacy of Venetoclax as a maintenance therapy alone or in combination with low dose cytarabine (LDAC).
Acute Myeloid Leukaemia (AML)
Australian Leukaemia and Lymphoma Group (ALLG)75 enrolled19 locationsACTRN12619000280101
Withdrawn
Phase 2
A Phase II study of midostaurin in combination with standard chemotherapy in newly diagnosed patients with Core Binding Factor Acute Myeloid Leukaemia
Core binding factor (CBF) Acute myeloid leukaemia (AML)
Australasian Leukaemia and Lymphoma Group50 enrolled1 locationACTRN12612000847819
Completed
Phase 2
Investigating the role of targeted therapy Sorafenib - the Fms-like tyrosine kinase 3 (FLT3) inhibitor, in combination with intensive chemotherapy, for previously untreated adult patients with Acute Myeloid Leukaemia (AML) with FLT3 mutations. A Phase II randomised placebo-controlled multi-centre study
Previously untreated adult acute myeloid leukaemia (AML) with FLT3-ITD mutation.
Leukaemia Foundation of Australia102 enrolled15 locationsACTRN12611001112954
Completed
Phase 2
Panobinostat with 5-azacytidine in patients with untreated high risk Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukaemia (AML).
Previously untreated high risk Myelodysplastic syndrome (MDS)Previously untreated Acute Myeloid Leukaemia (AML)
The Alfred Hospital40 enrolled1 locationACTRN12610000924055
Recruiting
Phase 2
Eltrombopag therapy for low platelets in patients on azacitidine treatment for myelodysplastic syndrome and acute myeloid leukaemia
Low marrow blast count acute myeloid leukaemia (AML)Myelodysplastic Syndromes (MDS)
Peter Mac Callum Cancer Centre25 enrolled1 locationACTRN12610000641099
Completed
Phase 2
Lenalidomide and 5azacitidine treatment versus 5azacitidine alone in patients with the blood cancers myelodysplastic syndrome or acute myeloid leukaemia
Low marrow blast count acute myeloid leukaemia (AML)
Australasian Leukaemia and Lymphoma Group160 enrolled1 locationACTRN12610000271000